Our goal is to be the leading biopharmaceutical company developing and marketing therapies that restore function and improve the lives of people with neurological disorders.

Acorda’s R&D efforts are designed to:

• Develop CVT-301 as a potential treatment for OFF periods in people with Parkinson’s disease
• Determine if dalfampridine is a therapeutic option for people with post-stroke walking difficulties
• Advance CVT-427 as a potential acute treatment for migraine
• Advance clinical development of rHIgM22, a remyelinating antibody, as a potential treatment for people with MS

Show/Hide Pipeline